Company

Avacta Group (LSE:AVCT)

Avacta is an early-stage biotech firm specialising in the fields of diagnostics and therapeutics. Its diagnostics division created a proprietary platform called Affimer. It consists of a portfolio of reagent proteins that can be used to detect specific infections within a given sample. Traditionally this process is achieved using antibodies. However, manufacturing antibodies is a complex, time-consuming process that Affimer reagents don’t have to go through. In 2020, Avacta leveraged its Affimer platform to create Covid-19 lateral flow tests. This was the catalyst behind the AVCT share price spike that year. On the therapeutics side of the business, the company is currently testing its flagship AVA6000 chemotherapy drug in clinical trials. This treatment is being developed with the group’s second chemical platform called pre|CISION. Unlike existing chemotherapy treatments, AVA6000 is highly targeted, resulting in less healthy cells being caught in the crossfire, and reducing the severity of side effects.

About AVCT

Related Articles

Investing Articles

2 Penny shares I’d avoid like the plague

Penny shares can deliver enormous returns for investors willing to take on additional risk, but not all of them are…

Read more »

Investing Articles

What’s next for the Avacta share price?

The Avacta share price has crashed by almost 80%! But is this a buying opportunity for patient investors? Zaven Boyrazian…

Read more »

Blue question mark background and dark space
Investing Articles

The Avacta share price: buy or avoid like the plague?

With two revolutionary cancer treatments, is Avacta becoming increasingly attractive?

Read more »

Investing Articles

What’s going on with the Avacta share price?

This Fool explains why he thinks the Avacta share price has been underperforming, and the catalyst that could cause a…

Read more »

Investing Articles

The Avacta (AVCT) share price has halved since May. Can it make a comeback?

The Avacta (LON:AVCT) share price continues to tumble on rising costs, but can it make a comeback? Zaven Boyrazian investigates.

Read more »

Investing Articles

Is the Avacta (AVCT) share price about to explode?

The Avacta (AVCT) share price may be about to explode! Zaven Boyrazian takes a closer look at what's got investors…

Read more »

Investing Articles

Why did the Avacta share price crash in 2021?

The Avacta share price has crashed by 50% in the last three months. Zaven Boyrazian investigates what's causing this downward…

Read more »

Investing Articles

The Avacta share price is soaring. Should I buy?

The Avacta share price jumped yesterday by almost 5%. But have I missed my opportunity? Here’s my take on the…

Read more »

Investing Articles

Can the Avacta share price keep climbing?

The Avacta share price has seen some explosive growth over the last 12 months but can this momentum continue? Zaven…

Read more »

Investing Articles

The Avacta share price (AVCT) has climbed 1,400%. Here’s what I’d do now

The biotech sector has been one to watch since Covid-19 arrived. Could the Avacta Group share price be the one…

Read more »

Frequently Asked Questions

Avacta was listed on the London Stock Exchange Alternative Investment Market in October 2003 through a reverse takeover. The split-adjusted floating price was 5,250p.

No. According to the 2020 annual report, Avacta does not pay dividends to shareholders, nor has it proposed to do so in the future.